Loading
Loading
Research Overview
Melanocortin MC4R agonist; activates central nervous system melanocortin pathways in the hypothalamus to initiate sexual arousal independent of vascular mechanisms, unlike PDE5 inhibitors. First FDA-approved treatment for HSDD.
PT-141 (bremelanotide) is a synthetic cyclic peptide that functions as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. It was derived from Melanotan-II through structural modification and has been studied in preclinical settings for its central nervous system melanocortin receptor engagement, particularly at MC3R and MC4R subtypes expressed in hypothalamic and limbic brain regions associated with sexual behaviour regulation.
In preclinical behavioural neuroscience research, PT-141 has been studied in animal models examining melanocortin-regulated aspects of sexual behaviour. Rodent model studies have used standardised sexual behaviour paradigms to characterise how central melanocortin receptor agonism by PT-141 influences behavioural endpoints in laboratory settings.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pt-141 (bremelanotide) melanocortin has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
PT-141 (Bremelanotide) Melanocortin research is most relevant to protocols examining:
Hypoactive sexual desire disorder (HSDD) research
CNS melanocortin MC4R pathway and sexual behaviour studies
Researchers studying vascular-independent arousal mechanisms
Male and female sexual dysfunction investigations
Initial phase
Effects begin quickly. Initial signalling starts within the first few days. Start at the lowest dose and assess tolerance.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~60–90 min active). Review data, confirm baseline recovery before any repeat protocol.
Melanocortin MC4R agonist; activates central nervous system melanocortin pathways in the hypothalamus to initiate sexual arousal independent of vascular mechanisms, unlike PDE5 inhibitors. First FDA-approved treatment for HSDD.
| Parameter | Value |
|---|---|
| Dose range | 1.75 mg per dose |
| Schedule | As needed (≥45 min before activity) |
| Route | Subcutaneous |
| Half-life | ~60–90 min active |
dose-dependent)
Poppers (amyl nitrate / isobutyl nitrate): severe acute hypotension
both compounds lower blood pressure via different mechanisms; combination is potentially dangerous
PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra)
additive blood pressure reduction; clinical trial data shows augmented hypotensive effect when combined
Antihypertensive medications (beta-blockers, ACE inhibitors, calcium channel blockers)
additive hypotension risk
MDMA / ecstasy
significant cardiovascular overstimulation when MC4R activation is layered with the hypertensive and tachycardic effects of MDMA
Cocaine: dangerous combined cardiovascular effects
both stimulate the autonomic nervous system in opposing and chaotic ways
Alcohol
reduces vasomotor tone and may amplify flushing, nausea, and dizziness from PT-141
Nausea medications (ondansetron, metoclopramide)
these may need to be kept on hand; ondansetron does not interact negatively and is commonly used to manage PT-141 nausea
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
